The Cuban drug Nimotuzumab demonstrated its effectiveness and safety in patients in severe and moderate condition with Covid-19, as stated by the director of Clinical Research at the Center for Molecular Immunology, Tania Crombet, who pointed out that studies with the monoclonal antibody CIMAher® revealed an improvement in ventilatory function and a reduction in the concentration of interleukin 6.
«Interleukin 6 is one of the main cytokines that cause the hyperinflammatory state that those infected with the SARS-CoV-2 virus can present»
The specialist explained that the patients demonstrated a radiological improvement or stabilization of multifocal interstitial pneumonia in 80%, on the seventh day after receiving the first dose.
She explained that preliminary evidence of prevention or reversal of fibrotic lesions could be observed by computerized axial tomography, leading to a reduction in pulmonary sequelae.
Nimotuzumab obtained its sanitary registration in 2002 for the treatment of advanced tumors of the head and neck, when it was shown that it blocks or inhibits epidermal growth factor, a highly validated target in oncology, producing an inhibition of the uncontrolled proliferation of malignant cells, the formation of new vessels and the occurrence of metastasis.
The drug, Crombet added, also activates the immune system, Crombet noted, adding that Nimotuzumab is registered in 24 countries and has a special sales permit in 15 territories in Europe and other nations.
Source: Prensa Latina